BG108941A - Полиморф на 4-[2-[1-(2-етоксиетил)-1н-бензимидазол-2-ил]-1-пиперидинил]етил]-алфа алфа-диметил-фенилоцетна киселина - Google Patents

Полиморф на 4-[2-[1-(2-етоксиетил)-1н-бензимидазол-2-ил]-1-пиперидинил]етил]-алфа алфа-диметил-фенилоцетна киселина

Info

Publication number
BG108941A
BG108941A BG108941A BG10894104A BG108941A BG 108941 A BG108941 A BG 108941A BG 108941 A BG108941 A BG 108941A BG 10894104 A BG10894104 A BG 10894104A BG 108941 A BG108941 A BG 108941A
Authority
BG
Bulgaria
Prior art keywords
alpha
polymorph
benzeneacetic
ethoxyethyl
benzimidazole
Prior art date
Application number
BG108941A
Other languages
English (en)
Other versions
BG66302B1 (bg
Inventor
Aurelio Venero
Maravillas Martin
Gonzalo Mori
Haydee Fuente
DE PABLO Maria-Luisa LUCERO
Victor Royo
Ramon PESTANA
Original Assignee
Faes Farma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29225789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108941(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma S.A. filed Critical Faes Farma S.A.
Publication of BG108941A publication Critical patent/BG108941A/bg
Publication of BG66302B1 publication Critical patent/BG66302B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретението се отнася до полиморф 1 на 4-[2-[1-(2-етоксиетил)-1Н-,бензимидазол-2-ил]-1 -пиперидинил]етил1]-аа-диметил-фенил оцетна,киселина с формула (I), метод за получаването му, фармацевтични, формулации съдържащи полиморф 1, както и приложение на полиморф,1 за третиране на алергични реакции и патологични процеси протичащи@с посредничеството на хистамина, при плекопитаещи, такива като@човека.
BG108941A 2002-04-19 2004-11-18 Полиморф на диметил-бензен оцетна киселина BG66302B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2002/000194 WO2003089425A1 (es) 2002-04-19 2002-04-19 POLIMORFO DEL ÁCIDO 4-[2-[4-[1-(2-ETOXIETIL)-1H-BENCIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α-DIMETIL-BENCENOACÉTICO

Publications (2)

Publication Number Publication Date
BG108941A true BG108941A (bg) 2005-12-30
BG66302B1 BG66302B1 (bg) 2013-03-29

Family

ID=29225789

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108941A BG66302B1 (bg) 2002-04-19 2004-11-18 Полиморф на диметил-бензен оцетна киселина

Country Status (31)

Country Link
US (2) US7612095B2 (bg)
EP (1) EP1505066B1 (bg)
JP (1) JP5142448B2 (bg)
KR (1) KR100673140B1 (bg)
CN (1) CN1290843C (bg)
AR (1) AR039423A1 (bg)
AT (1) ATE347550T1 (bg)
AU (1) AU2002255017B2 (bg)
BG (1) BG66302B1 (bg)
BR (1) BRPI0215703B8 (bg)
CA (1) CA2484460C (bg)
CY (2) CY1107564T1 (bg)
CZ (1) CZ305162B6 (bg)
DE (1) DE60216641T2 (bg)
DK (1) DK1505066T3 (bg)
ES (1) ES2278018T3 (bg)
HK (1) HK1072772A1 (bg)
HR (1) HRP20041048B1 (bg)
HU (1) HU230032B1 (bg)
IL (1) IL164645A (bg)
MX (1) MXPA04010313A (bg)
NO (1) NO329327B1 (bg)
NZ (1) NZ536551A (bg)
PA (1) PA8571201A1 (bg)
PE (1) PE20040086A1 (bg)
PT (1) PT1505066E (bg)
SI (1) SI1505066T1 (bg)
SK (1) SK288052B6 (bg)
UA (1) UA76866C2 (bg)
UY (1) UY27762A1 (bg)
WO (1) WO2003089425A1 (bg)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
US20140194111A1 (en) * 2011-06-30 2014-07-10 Panasonic Corporation Communication system, user terminal, and communication device
CN102675101B (zh) * 2012-05-16 2014-01-29 王蕾 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
CN103214454A (zh) * 2013-03-30 2013-07-24 北京万全德众医药生物技术有限公司 一种比拉斯汀晶型及制备方法
WO2014188453A2 (en) * 2013-05-24 2014-11-27 Msn Laboratories Private Limited Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
CN103356616A (zh) * 2013-06-29 2013-10-23 北京万全德众医药生物技术有限公司 一种含有比拉斯汀的药物组合物及其制备方法
CN104447682A (zh) * 2013-09-12 2015-03-25 天津市汉康医药生物技术有限公司 比拉斯汀化合物
CN104398481A (zh) * 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
CA2993134A1 (en) * 2015-07-24 2017-02-02 Urquima, S.A. Crystalline forms of bilastine and preparation methods thereof
EP3170816A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds
EP3170817A1 (en) * 2015-11-20 2017-05-24 Faes Farma, S.A. Co-crystals of benzimidazole compounds
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine
EP3452462A4 (en) * 2016-05-05 2019-10-23 MSN Laboratories Private Limited, R&D Center SOLID STATE FORMS OF 2- [4- (2- {4- [1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOL-2-YL] -1-PIPERIDINYL} ETHYL) PHENYL] -2-METHYLPROPANOIC ACID AND PREPARATION METHOD THEREOF
ES2813561T3 (es) 2017-09-07 2021-03-24 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica en comprimido que comprende bilastina
ES2835287T3 (es) 2017-12-18 2021-06-22 Tiefenbacher Alfred E Gmbh & Co Kg Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio
PL3641735T3 (pl) 2017-12-18 2021-09-06 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Kompozycja farmaceutyczna tabletki zawierająca bilastynę w postaci 3 i rozpuszczalny w wodzie wypełniacz
CA3088740A1 (en) 2018-01-18 2019-07-25 Faes Farma, S.A. Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent
CA3200779A1 (en) 2020-12-23 2022-06-30 Strusi ORAZIO LUCA A non-micronized bilastine composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
BR0010683A (pt) * 1999-04-16 2003-07-01 Reddy Research Foundation Formas polimórficas de um agente antidiabético: processo para seu preparo e composições farmacêuticas contendo o mesmo
PE20010044A1 (es) * 1999-04-23 2001-03-10 Smithkline Beecham Plc Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona

Also Published As

Publication number Publication date
BRPI0215703B8 (pt) 2021-05-25
DE60216641T2 (de) 2007-09-27
KR100673140B1 (ko) 2007-01-22
UY27762A1 (es) 2003-09-30
DK1505066T3 (da) 2007-03-19
ATE347550T1 (de) 2006-12-15
PE20040086A1 (es) 2004-04-27
BR0215703A (pt) 2005-02-01
BG66302B1 (bg) 2013-03-29
EP1505066B1 (en) 2006-12-06
JP5142448B2 (ja) 2013-02-13
ES2278018T3 (es) 2007-08-01
CY2013015I2 (el) 2015-08-05
EP1505066A1 (en) 2005-02-09
JP2005529120A (ja) 2005-09-29
HK1072772A1 (en) 2005-09-09
US20050203141A1 (en) 2005-09-15
CA2484460C (en) 2009-09-29
CZ305162B6 (cs) 2015-05-27
PA8571201A1 (es) 2003-12-10
HRP20041048B1 (hr) 2013-04-30
BRPI0215703B1 (pt) 2017-06-27
US7612095B2 (en) 2009-11-03
WO2003089425A1 (es) 2003-10-30
NZ536551A (en) 2006-08-31
NO329327B1 (no) 2010-09-27
HRP20041048A9 (hr) 2013-01-31
SK288052B6 (sk) 2013-03-01
NO20044999L (no) 2005-01-14
DE60216641D1 (de) 2007-01-18
AU2002255017A1 (en) 2003-11-03
US20100004285A1 (en) 2010-01-07
AR039423A1 (es) 2005-02-16
CZ20041122A3 (cs) 2005-03-16
HRP20041048A2 (en) 2005-02-28
MXPA04010313A (es) 2005-06-08
CN1290843C (zh) 2006-12-20
KR20050005448A (ko) 2005-01-13
HU230032B1 (hu) 2015-05-28
CY2013015I1 (el) 2015-08-05
CA2484460A1 (en) 2003-10-30
AU2002255017B2 (en) 2008-11-13
HUP0500241A2 (hu) 2005-06-28
SI1505066T1 (sl) 2007-04-30
IL164645A0 (en) 2005-12-18
CY1107564T1 (el) 2013-03-13
IL164645A (en) 2010-11-30
SK50202004A3 (sk) 2005-05-05
UA76866C2 (uk) 2006-09-15
CN1628112A (zh) 2005-06-15
PT1505066E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
BG108941A (bg) Полиморф на 4-[2-[1-(2-етоксиетил)-1н-бензимидазол-2-ил]-1-пиперидинил]етил]-алфа алфа-диметил-фенилоцетна киселина
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2004046120A3 (en) Diaminotriazoles useful as inhibitors of protein kinases
HK1087700A1 (en) Triazolopyridazines as protein kinases inhibitors
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
EP1887007A3 (en) Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2005011581A3 (en) Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease